FCCP, mitochondrial oxidative phosphorylation uncoupler (ab120081)
Key features and details
- Potent mitochondrial oxidative phosphorylation uncoupler
- CAS Number: 370-86-5
- Soluble in DMSO to 100 mM
- Form / State: Solid
- Source: Synthetic
Overview
-
Product name
FCCP, mitochondrial oxidative phosphorylation uncoupler -
Description
Potent mitochondrial oxidative phosphorylation uncoupler -
Biological description
Potent mitochondrial oxidative phosphorylation uncoupler (IC50 = 20 nM). Disrupts ATP synthesis by transporting protons across mitochondrial inner membranes. Depolarises mitochondrial membrane potential.
-
CAS Number
370-86-5 -
Chemical structure
Properties
-
Chemical name
Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone -
Molecular weight
254.17 -
Molecular formula
C10H5F3N4O -
PubChem identifier
330 -
Storage instructions
Store at +4°C. Store under desiccating conditions. The product can be stored for up to 12 months. -
Solubility overview
Soluble in DMSO to 100 mM -
Handling
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Toxic, refer to SDS for further information.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES
FC(F)(F)Oc1ccc(cc1)NN=C(/C#N)C#N -
Source
Synthetic
-
Research areas
Associated products
-
Alternative Versions
Images
-
Chemical Structure - FCCP, mitochondrial oxidative phosphorylation uncoupler (ab120081)2D chemical structure image of ab120081, FCCP, mitochondrial oxidative phosphorylation uncoupler
-
Cellular activation - FCCP, mitochondrial oxidative phosphorylation uncoupler (ab120081)Image from Chan G K Y, et al. Plos One, 8(5), e63583. Fig S4,; doi: 10.1371/journal.pone.0063583HT29 cells were treated with the indicated compounds ((etoposide, 10 µM; gemcitabine 0.1 µM; paclitaxel 0.01 µM; PD901 1 µM, VX-680 0.2 µM) for 24 hours before analysis of oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) using the Seahorse XF96 extracellular flux analyzer. Baseline rates (black) were determined at the indicated times before the addition of oligomycin (green) and then FCCP (red). Rate data are normalized to per-well cell number determined by post-analysis high-content imaging.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
References (35)
ab120081 has been referenced in 35 publications.
- Sautchuk R et al. Transcriptional regulation of cyclophilin D by BMP/Smad signaling and its role in osteogenic differentiation. Elife 11:N/A (2022). PubMed: 35635445
- Moya ELJ et al. Miniaturization and Automation of a Human In Vitro Blood-Brain Barrier Model for the High-Throughput Screening of Compounds in the Early Stage of Drug Discovery. Pharmaceutics 13:N/A (2021). PubMed: 34208550
- Meyer FB et al. Butyrate and Metformin Affect Energy Metabolism Independently of the Metabolic Phenotype in the Tumor Therapy Model. Biomolecules 11:N/A (2021). PubMed: 34944475
- Morgenstern M et al. Quantitative high-confidence human mitochondrial proteome and its dynamics in cellular context. Cell Metab 33:2464-2483.e18 (2021). PubMed: 34800366
- Blancke Soares A et al. High-resolution spatiotemporal pHe and pO2 imaging in head and neck and oesophageal carcinoma cells. Cancer Metab 9:21 (2021). PubMed: 33947450